Special symposia

Thursday 25 October, 12.15 – 13.15

Hall: Auditorium

Special symposium by Daiichi Sankyo

Date: Thursday 25 October

Time: 12:15-13:15

Hall: Auditorium

 

The role of direct oral anticoagulants in cancer-related VTE

  • Welcome and introduction, Harry Büller (the Netherlands)
  • From CLOT to CATCH: LMWH for VTE in cancer patients, Peter Verhamme (Belgium)
  • Challenges of treating cancer related VTE: oncologist perspectives, Hanno Riess (Germany)
  • New standard of care for VTE treatment in cancer patients: DOAC is the answer? Cihan Ay (Austria)
  • Q&A

Thursday 25 October, 12.15 – 13.15

Hall: Callelongue

Special symposium by CSL Behring

Date: Thursday 25 October

Time: 12:15-13:15

Hall: Callelongue

 

Beliefs and attitudes towards pharmacokinetics: from design to practice

  • Pharmacokinetics: which reading for which use? Sylvain Goutelle (France)
  • PK based clinical management: helpful or trendy ? Philippe Nguyen (France)
  • Impact of post-translational changes on PK parameters of a recombinant coagulation factor, Peter Lenting (France) 

Thursday 25 October, 12.15 – 13.15

Hall: Endoume 1

Special symposium by Octapharma

Date: Thursday 25 October

Time: 12:15-13:15

Hall: Endoume 1

 

Addressing the needs of individuals with haemophilia A or von Willebrand disease

  • Welcome and introduction by the Chair, Yesim Dargaud
  • Going further with simoctocog alfa: Addressing the individual needs of people with haemophilia A, Carmen Escuriola Ettingshausen
  • Taking FVIII into the future: The development of a subcutaneous recombinant human FVIII for the treatment of haemophilia A, Christoph Kannicht
  • Real-world experience with a 1:1 VWF/FVIII concentrate in patients with von Willebrand disease, Erik Berntorp
  • Discussion and Conclusions, Yesim Dargaud

More information can be found here.

Thursday 25 October, 12.15 – 13.15

Hall: Endoume 2

Special symposium by Sobi

Date: Thursday 25 October

Time: 12:15-13:15

Hall: Endoume 2

 

Joint health in hemophilia patients : toward a new era ?

Chairman: Pr Chambost (France)

  • French Haemophilia National Registry Analysis: Data from « FranceCoag Network » R. d’Oiron (France)
  • Use of Ultrasonography in Hemophilia Treatment Centers: the next step to elevate the standard of care ? C. Martinoli (Italy)
  • Joint health in hemophilia: from current approaches to future perspectives, J. Oldenburg (Germany)
  • Discussion